Zurampic
(lesinurad)PreclinicalSmall molecule
Zurampic is a small molecule that works as a Solute Carrier Family 22 Member 12 Inhibitor.[2] It is being investigated across 2 indications, with its most advanced program in Preclinical.[1]
Zurampic is one of 52 small molecule programs targeting Hyperuricemia. It is currently in Preclinical.
2
Indications
19
Total Trials
0
Active Trials
51
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
47 competitors in Hyperuricemia
#DrugCompanyPhaseTrials
1Uloric
TakedaApproved
Farxiga
AstraZenecaApproved
Medrol
PfizerApproved
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Decadron
AAspen Global Incorporated
Approved
Zyloprim
Alnylam PharmaceuticalsPhase 2
Colcrys
Alnylam PharmaceuticalsPhase 2
Dotinurad
EisaiApproved
Febuxostat Tab
XXuhui Central Hospital, Shanghai
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia5 trials
Interaction4 trials
Gout2 trials
Monotherapy2 trials
3 more indications
Tophaceous Gout1 trial
Safety and Efficacy1 trial
Regulatory
FDA Approval Timeline[4]
Dec 22, 2015
ZURAMPIC
NDA NDA207988
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for lesinurad. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Solute Carrier Family 22 Member 12 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIronwood Pharmaceuticals, Inc.